Project Grant R50CA293244
Award Date 9/1/25
Completion Date 8/31/30
Dollars Obligated $136K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Kansas City, KS 66160, USA
Similar Awards
- The University of Kansas Medical Center Research Institute, Inc. (KUMCRI) has been awarded a $135,951 Project Grant from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to enhance access to breast cancer prevention clinical trials. The project aims to modernize engagement and delivery of cancer prevention research, with a focus on improving recruitment and representation of all populations in breast cancer prevention trials. The award supports research initiatives to...
- This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides funding to Case Western Reserve University to conduct research aimed at understanding the fundamental biological mechanisms of acute myeloid leukemia (AML) and developing new therapeutic approaches. The $491,357 award supports investigations into using proteasome inhibitors and an mTORC1 activator molecule to induce metabolic stress and resensitize AML cells to treatment, particularly...
- This $640,135 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to develop a new generation of potent menin inhibitors that can overcome resistance observed in current menin inhibitor treatments for acute myeloid leukemia (AML) patients. The award recipient, the Regents of the University of Michigan, will leverage its expertise in medicinal chemistry and cancer biology to design and test these next-generation menin...
- This $495,715 Project Grant awarded by the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research by the Sloan-Kettering Institute for Cancer Research to decipher the pathogenesis and therapeutic vulnerabilities of acute myeloid leukemia (AML) driven by germline RUNX1 mutations. The project aims to develop faithful preclinical models, including genetically engineered mouse models and patient-derived xenografts, to study the genetic events and disease progression from...
- This $458,698 federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research at the University of Michigan to identify cellular and molecular mechanisms underlying therapy resistance and disease relapse in acute myeloid leukemia (AML). The project aims to characterize genes and pathways that confer growth advantages to leukemic stem cells, enabling them to persist and regenerate disease after initial clinical remission. This 5-year...
- This five-year $360,281 Project Grant from the National Cancer Institute, part of the Department of Health and Human Services, will fund research under the Cancer Biology Research program (CFDA 93.396). The grantee, Washington University, will conduct studies to define the contribution of altered epigenetic patterns and genome organization to the pathogenesis of acute myeloid leukemia (AML). Researchers will perform comprehensive epigenetic analysis of DNA methylation and three-dimensional...
- This $683,472 Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the development of a novel targeted therapy for acute myeloid leukemia (AML). The principal investigators at the University of Cincinnati are conducting preclinical research to evaluate a differentiation-inducing agent (HOSU-53) that targets the mitochondrial enzyme DHODH. The goal is to promote AML cell differentiation, activate the immune system, and induce ferroptosis to...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $415,259 to the Rector & Visitors of the University of Virginia to conduct research on the role of long noncoding RNAs in acute myeloid leukemia (AML). The project aims to 1) determine the role of a specific regulatory RNA in primary and relapsed AML, and 2) define the mechanism underlying its deregulation in AML. This research will provide insights into how noncoding RNAs...
- This Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Biology Research program (CFDA 93.396), provides $487,542 to the Beckman Research Institute of the City of Hope to conduct research aimed at understanding the role of mitochondrial RNA methylation in acute myeloid leukemia (AML), particularly for high-risk AML subtypes. The key objectives are to determine the functional importance of the mitochondrial methyltransferase METTL17 in AML pathogenesis, dissect...
- This $194,688 Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program) supports research by Indiana University Indianapolis to investigate the role of the GATA2 gene in acute myeloid leukemia (AML) and the MonoMAC syndrome. The key objectives are to: 1) Define the genes regulated by the normal GATA2 protein and how their expression is altered by AML- and MonoMAC-associated GATA2 mutations, using a novel mouse model and overexpression studies in...